Citizens National Bank Trust Department bought a new position in Amrize Ltd (NYSE:AMRZ – Free Report) during the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 10,458 shares of the company’s stock, valued at approximately $504,000.
Several other large investors have also added to or reduced their stakes in AMRZ. Global Retirement Partners LLC bought a new stake in Amrize during the 3rd quarter worth approximately $48,000. BNP Paribas Financial Markets bought a new stake in Amrize during the second quarter worth $59,000. Groupe la Francaise purchased a new stake in Amrize in the 2nd quarter valued at $60,000. Allianz SE bought a new position in Amrize during the 2nd quarter valued at $80,000. Finally, Osaic Holdings Inc. bought a new position in Amrize during the 2nd quarter valued at $90,000.
Insider Transactions at Amrize
In other news, Director Nicholas C. Gangestad acquired 2,000 shares of the stock in a transaction that occurred on Wednesday, November 19th. The shares were acquired at an average cost of $47.34 per share, for a total transaction of $94,680.00. Following the purchase, the director owned 4,958 shares of the company’s stock, valued at approximately $234,711.72. The trade was a 67.61% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Jan Philipp Jenisch acquired 55,000 shares of the company’s stock in a transaction on Thursday, October 30th. The shares were acquired at an average cost of $52.64 per share, for a total transaction of $2,895,200.00. Following the completion of the acquisition, the chief executive officer owned 1,505,000 shares of the company’s stock, valued at approximately $79,223,200. The trade was a 3.79% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders bought 65,000 shares of company stock worth $3,399,720 over the last quarter.
Amrize Stock Down 2.5%
Amrize (NYSE:AMRZ – Get Free Report) last posted its quarterly earnings data on Wednesday, October 29th. The company reported $0.98 EPS for the quarter, missing the consensus estimate of $1.01 by ($0.03). The company had revenue of $3.68 billion during the quarter, compared to analyst estimates of $3.49 billion. The company’s quarterly revenue was up 6.6% on a year-over-year basis.
Analysts Set New Price Targets
Several research firms have recently issued reports on AMRZ. Wall Street Zen upgraded shares of Amrize to a “hold” rating in a research note on Saturday, October 25th. Stephens assumed coverage on shares of Amrize in a research report on Friday, November 14th. They issued an “overweight” rating and a $60.00 price objective for the company. Vertical Research initiated coverage on shares of Amrize in a research note on Tuesday, November 25th. They issued a “hold” rating and a $54.00 price objective for the company. Deutsche Bank Aktiengesellschaft set a $59.00 target price on shares of Amrize in a research report on Monday, December 8th. Finally, Citigroup upped their target price on Amrize from $60.00 to $63.00 and gave the company a “buy” rating in a report on Monday, November 3rd. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and seven have issued a Hold rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $60.00.
About Amrize
Amrize AG focuses on building materials business in North America. The company was incorporated in 2023 and is based in Zug, Switzerland. Amrize AG operates independently of Holcim AG as of June 23, 2025.
Featured Stories
- Five stocks we like better than Amrize
- You Still Think Silver’s a Joke? Watch What Happens Next.
- A U.S. “birthright” claim worth trillions – activated quietly
- A month before the crash
- Wall Street ‘Sleeper Stock’ Could Become #1 Stock of 2026
- YDES Could Be 2026’s Biotech Breakthrough
Receive News & Ratings for Amrize Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amrize and related companies with MarketBeat.com's FREE daily email newsletter.
